NaHS ameliorates diabetic vascular injury by correcting depressed connexin 43 and 40 in the vasculature in streptozotocin-injected rats

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 5, 2010, Pages 615-621

  Zheng, Yu Fen ^a   Dai, De Zai ^a   Dai, Yin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Connexin; Diabetes; NADPH oxidase; NaHS; PKC

Indexed keywords

AMINOGUANIDINE; ANTIOXIDANT; CONNEXIN 40; CONNEXIN 43; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PROTEIN KINASE C EPSILON; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE P22PHOX SUBUNIT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE P47PHOX SUBUNIT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE P67PHOX SUBUNIT; SODIUM HYDROSULFIDE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DRUG EFFICACY; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HYPERGLYCEMIA; MALE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; THORACIC AORTA; VASODILATATION; VASOSPASM;

EID: 84940527008     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.05.0009     Document Type: Article

References (40)

1. Mehta JL et al. Oxidative stress in diabetes: a mechanistic overview of its effects on atherogenesis and myocardial dysfunction. Int J Biochem Cell Biol 2006 38 : 794 803.
2. Orasanu G et al. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 2009 53 : 35 42.
3. Nemsadze K et al. Mechanisms of lead-induced poisoning. Georgian Med News 2009 172-173 : 92 96.
4. King GL et al. Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol 2004 122 : 333 338.
5. Li N et al. CPU86017 and its isomers improve hypoxic pulmonary hypertension by attenuating increased ETA receptor expression and extracellular matrix accumulation. Naunyn Schmiedebergs Arch Pharmacol 2008 378 : 541 552.
6. Xu J et al. The endothelin receptor antagonist CPU0213 is more effective than aminoguanidine to attenuate isoproterenol-induced vascular abnormality by suppressing overexpression of NADPH oxidase, ETA, ETB, and MMP9 in the vasculature. J Cardiovasc Pharmacol 2008 52 : 42 48.
7. Luksha L et al. Endothelium-derived hyperpolarizing factor in vascular physiology and cardiovascular disease. Atherosclerosis 2009 202 : 330 344.
8. Priccif F et al. Oxidative stress in diabetes-induced endothelial dysfunction involvement of nitric oxidase and protein kinase C. Free Radic Biol Med 2003 35 : 683 694.
9. Böhm F et al. Vitamin C blocks vascular dysfunction and release of interleukin-6 induced by endothelin-1 in humans in vivo. Atherosclerosis 2007 190 : 408 415.
10. Su W et al. Upregulated endothelin system in diabetic vascular dysfunction and early retinopathy is reversed by CPU0213 and total triterpene acids from Fructus Corni. Clin Exp Pharmacol Physiol 2007 34 : 1228 1233.
11. Garaliene V. Endothelium and nitric oxide. Medicina (Kaunas) 2008 44 : 564 569 [Lithuanian].
12. Black SM et al. Oxidative and nitrosative stress in pediatric pulmonary hypertension: roles of endothelin-1 and nitric oxide. Vasc Pharmacol 2006 45 : 308 316.
13. Channon KM, Guzik TJ. Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. J Physiol Pharmacol 2002 53 : 515 524.
14. Goldberg IJ, Dansky HM. Diabetic vascular disease. Arterioscler Thromb Vasc Biol 2006 26 : 1693 1701.
15. Dhein S. Pharmacology of gap junctions in the cardiovascular system. Cardiovasc Res 2004 62 : 287 298. (Pubitemid 38496542)
16. Söhl G et al. Gap junctions and the connexin protein family. Cardiovasc Res 2004 62 : 228 232.
17. Sato T et al. Downregulation of connexin 43 expression by high glucose reduces gap junction activity in microvascular endothelial cells. Diabetes 2002 51 : 1565 1571.
18. Haussig S et al. Sub-chronic nicotine exposure induces intercellular communication failure and differential down-regulation of connexins in cultured human endothelial cells. Atherosclerosis 2008 196 : 210 218.
19. Sirnes S et al. Interplay between PKC and the MAP kinase pathway in Connexin43 phosphorylation and inhibition of gap junction intercellular communication. Biochem Biophys Res Commun 2009 382 : 41 45.
20. Heyman NS et al. Regulation of gap junctional charge selectivity in cells coexpressing connexin 40 and connexin 43. Am J Physiol Heart Circ Physiol 2009 297 : 450 459.
21. Kaneko Y et al. Glucose-induced production of hydrogen sulfide may protect the pancreatic beta-cells from apoptotic cell death by high glucose. FEBS Lett 2009 583 : 377 382.
22. Srilatha B et al. Possible role for the novel gasotransmitter hydrogen sulphide in erectile dysfunction - a pilot study. Eur J Pharmacol 2006 535 : 280 282.
23. Matta SGC et al. Effect of inhibition of synthesis of inducible nitric oxide synthase-derived nitric oxide by aminoguanidine on the in vitro maturation of oocyte-cumulus complexes of cattle. Anim Reprod Sci 2009 111 : 189 201.
24. Stadler K et al. Aminoguanidine prevents peroxynitrite production and cardiac hypertrophy in streptozotocin-induced diabetic rats. Orv Hetil 2004 145 : 2491 2496.
25. Chang KC et al. Aminoguanidine prevents arterial stiffening and cardiac hypertrophy in streptozotocin-induced diabetes in rats. Br J Pharmacol 2006 147 : 944 950.
26. Su J et al. Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice. Arterioscler Thromb Vasc Biol 2008 28 : 1432 1438.
27. Zhang TT et al. Pharmacological efficacy of CPU86017 on hypoxic pulmonary hypertension in rats: mediated by direct inhibition of calcium channels and antioxidant action, but indirect effects on the ET-1 pathway. J Cardiovasc Pharmacol 2005 46 : 727 734.
28. Wagner F et al. Bench-to-bedside review: hydrogen sulfide-the third gaseous transmitter: applications for critical care. Crit Care 2009 13 : 213.
29. Yusuf M et al. Streptozotocin-induced diabetes in the rat is associated with enhanced tissue hydrogen sulfide biosynthesis. Biochem Biophys Res Commun 2005 333 : 1146 1152.
30. Whiteman M, Moore PK. Hydrogen sulfide and the vasculature: a novel vasculoprotective entity and regulator of nitric oxide bioavailability J Cell Mol Med 2009 13 : 488 507.
31. Li L, Watts SW. Endothelin-1 increases vascular superoxide via endothelin A-NADPH oxidase pathway in low-renin hypertension. Circulation 2003 107 : 1053 1058.
32. Selemidis S et al. NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther 2008 120 : 254 291.
33. 2+]i in pulmonary artery smooth muscle cells. Biochem Biophys Res Commun 2006 351 : 784 790.
34. Jeney V et al. Suppression of hemin-mediated oxidation of low-density lipoprotein and subsequent endothelial reactions by hydrogen sulfide (H(2)S). Free Radic Biol Med 2009 46 : 616 623.
35. Herve JC et al. Gap junctional complexes: from partners to functions. Prog Biophys Mol Biol 2007 94 : 29 65.
36. Salameh A et al. Pharmacology of gap junctions. New pharmacological targets for treatment of arrhythmia, seizure and cancer Biochim Biophys Acta 2005 1719 : 36 58.
37. Figueroa XF. Histamine reduces gap junctional communication of human tonsil high endothelial cells in culture. Microvasc Res 2004 68 : 247 257.
38. Mancardi D et al. Physiological and pharmacological features of the novel gasotransmitter: hydrogen sulfide. Biochim Biophys Acta 2009 1787 : 864 872.
39. Ji Y et al. Exogenous hydrogen sulfide postconditioning protects isolated rat hearts against ischemia-reperfusion injury. Eur J Pharmacol 2008 587 : 1 7.
40. Brooks BA et al. The effects of diabetes and aminoguanidine treatment on endothelial function in a primate model of type 1 diabetes. Am J Primatol 2008 70 : 796 802.